

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

**3DMed**

**思路迪**

**3D Medicines Inc.**

**思路迪医药股份有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code: 1244)**

## **ADOPTION OF CHINESE NAME AND CHANGE OF STOCK SHORT NAME**

The Board is pleased to announce that the adoption of “思路迪医药股份有限公司” as the dual foreign name in Chinese of the Company has become effective.

The Chinese stock short name of “思路迪醫藥股份” for trading of the Shares on the Stock Exchange will become effective from 9:00 a.m. on August 5, 2024. The English stock short name of “3D MEDICINES” and the stock code of “1244” of the Company and other trading arrangements in relation to the Shares will remain unchanged.

References are made to the announcement of 3D Medicines Inc. (the “**Company**”) dated June 3, 2024, the circular of the Company dated June 5, 2024 (the “**Circular**”) and the poll results announcement of the Company dated June 28, 2024, in relation to, among others, the adoption of the Chinese name “思路迪医药股份有限公司” as the dual foreign name of the Company (the “**Adoption of Chinese Name**”). Unless otherwise defined, capitalised terms used herein shall have the same meanings as those used in the Circular.

### **ADOPTION OF CHINESE NAME**

The Board is pleased to announce that the Chinese name of “思路迪医药股份有限公司” has been adopted as the dual foreign name of the Company. The Shareholders approved the Adoption of Chinese Name at the annual general meeting of the Company held on June 28, 2024. The Certificate of Incorporation on Adoption of Dual Foreign Name of the Company was issued by the Registrar of Companies in the Cayman Islands on July 8, 2024. The Certificate of Registration of Alteration of Name of Registered Non-Hong Kong Company was issued by the Registrar of Companies in Hong Kong on July 23, 2024.

## **ADOPTION OF CHINESE STOCK SHORT NAME**

The Chinese stock short name of the Company “思路迪醫藥股份” for trading of Shares of the Company on the Stock Exchange will become effective from 9:00 a.m. on August 5, 2024. The English stock short name of “3D MEDICINES” and the stock code of “1244” of the Company and other trading arrangements in relation to the Shares will remain unchanged.

## **EFFECT OF THE ADOPTION OF CHINESE NAME**

The Adoption of Chinese Name will not affect the rights of any Shareholders or the Company’s daily business operation and its financial position. All existing share certificates of the Company bearing the existing names of the Company will, after the Adoption of Chinese Name becomes effective, continue to be evidence of legal title to the shares of the Company and valid for trading, settlement, registration and delivery purposes. Accordingly, there will not be any arrangement for the free exchange of the existing share certificates for new share certificates bearing both the English name and dual foreign name of the Company. Any issue of new share certificates thereafter will bear both the existing English name and the new Chinese name of the Company.

By order of the Board  
**3D Medicines Inc.**  
**Dr. Gong Zhaolong**  
*Chairman of the Board*

Hong Kong, July 30, 2024

*As at the date of this announcement, the Board of Directors of the Company comprises Dr. GONG Zhaolong as executive Director, Mr. ZHU Pai, Mr. ZHOU Feng and Ms. CHEN Yawen as non-executive Directors, and Dr. LI Jin, Dr. LIN Tat Pang and Mr. LIU Xinguang as independent non-executive Directors.*